The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.
The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
Clinical Trials Arena on MSN13d
MacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...
OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback